StreetInsider.com News Articles

Form 8-K TELA Bio, Inc. For: Oct 08

Thu, 08 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261008/27167017.html

Form 8-K TELA Bio, Inc. For: Oct 05

Tue, 06 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261006/27155468.html

FDA clears TELA Bio's Liora resorbable surgical mesh device

Mon, 05 Oct 2026 08:05:11 -0400

TELA Bio, Inc. (NASDAQ: TELA) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh device intended for soft tissue reinforcement.

According to the company, Liora is the first product to be fully developed in TELA Bio's ISO 8 certified cleanroom in Malvern, Pa., and the first fully resorbable synthetic product in its portfolio to be designed and produced in-house.

"FDA 510(k) clearance is a significant milestone for TELA Bio as Liora is the first fully resorbable synthetic product in our portfolio to be designed and produced in-house by our

Form 8-K TELA Bio, Inc. For: Oct 05

Mon, 05 Oct 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20261005/27146045.html

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

Mon, 05 Oct 2026 08:00:00 -0400

MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product.

Liora is a fully resorbable surgical mesh device for soft tissue reinforcement that will enable TELA Bio to expand its footprint in the soft tissue reconstruction market and is the first implant to be fully developed in the Company’s ISO 8 certified cleanroom in Malvern, PA.

“FDA

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

Mon, 05 Oct 2026 08:00:00 -0400

“FDA

Form 8-K TELA Bio, Inc. For: Sep 28

Tue, 29 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260929/27122438.html

Craig-Hallum Starts TELA Bio, Inc. (TELA) at Buy

Fri, 25 Sep 2026 07:10:03 -0400

Craig-Hallum analyst Chase Knickerbocker initiates coverage on TELA Bio, Inc. (NASDAQ: TELA) with a Buy rating and a price target of $2.00.

For an analyst ratings summary and ratings history on TELA Bio, Inc. click here. For more ratings news on TELA Bio, Inc. click here.

Shares of TELA Bio, Inc. closed at $1.27 yesterday.

Form 4 TELA Bio, Inc. For: Sep 16 Filed by: Capper Joseph H

Fri, 18 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260918/27080873.html

Form 8-K TELA Bio, Inc. For: Sep 15

Fri, 18 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260918/27080559.html

Form 4 TELA Bio, Inc. For: Sep 14 Filed by: Capper Joseph H

Wed, 16 Sep 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260916/27071422.html

Form DEF 14A TELA Bio, Inc. For: Oct 08

Mon, 14 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260914/27058400.html

TELA Bio to cut 20% of workforce, expects $1.5M in charges

Mon, 31 Aug 2026 07:13:11 -0400

TELA Bio, Inc. (NASDAQ: TELA) announced that its Board of Directors approved a workforce reduction plan on August 28, 2026, cutting approximately 20% of its employees as part of an effort to reduce operating expenses.

The plan will reduce the company's headcount from 201 to approximately 160 full-time employees. The reduction is expected to be substantially completed during the third quarter of 2026.

The company estimates it will incur aggregate charges of approximately $1.5 million related to the plan, consisting primarily of severance and other employee-related costs. The company expects substantially all of these charges to result in cash expenditures during the

TELA Bio to cut 20% of workforce, expects $1.5M in charges

Mon, 31 Aug 2026 07:13:11 -0400

The plan will reduce the company's headcount from 201 to approximately 160 full-time employees. The reduction is expected to be substantially completed during the third quarter of 2026.

TELA Bio cuts costs by $17M and replaces COO/CFO

Mon, 31 Aug 2026 07:00:39 -0400

TELA Bio, Inc. (NASDAQ: TELA) announced that Roberto Cuca, its Chief Operating Officer and Chief Financial Officer, stepped down effective Aug. 31, 2026, alongside a cost reduction initiative targeting $17.0 million in annual operating expense savings.

The Malvern, Pa.-based medical technology company said the savings will be driven by a headcount reduction of approximately 20% and the streamlining of external resources. The company said it expects the initiative to extend its cash runway into 2028.

TELA Bio anticipates a one-time restructuring charge of approximately $1.5 million in the third quarter of 2026, primarily related to severance and other employee-related costs. The company

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

Mon, 31 Aug 2026 07:00:00 -0400

Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program

MALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role effective today.

“On behalf of the Board and management team, I would like to thank Roberto for his many contributions to TELA Bio over the past five years,” said Heather Getz, Chief Executive Officer of

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

Mon, 31 Aug 2026 07:00:00 -0400

Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program

“On behalf of the Board and management team, I would like to thank Roberto for his many contributions to TELA Bio over the past five years,” said Heather Getz, Chief Executive Officer of

Form 4 TELA Bio, Inc. For: Aug 17 Filed by: Getz Heather C

Tue, 25 Aug 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26975976.html

Form 4 TELA Bio, Inc. For: Aug 17 Filed by: Getz Heather C

Tue, 25 Aug 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26975976.html

Form 4 TELA Bio, Inc. For: Aug 17 Filed by: Getz Heather C

Wed, 19 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260819/26950147.html

Form 4 TELA Bio, Inc. For: Aug 17 Filed by: Getz Heather C

Wed, 19 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260819/26950147.html

Form 4 TELA Bio, Inc. For: Aug 14 Filed by: Getz Heather C

Mon, 17 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26938416.html

Form 4 TELA Bio, Inc. For: Aug 14 Filed by: Getz Heather C

Mon, 17 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26938416.html

Form SCHEDULE 13G/A TELA Bio, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932118.html

Form SCHEDULE 13G/A TELA Bio, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932118.html